Key result
Angio-Seal nondeployment drops ~75% after the initial 50-case learning curve.
Why the study?
The frequency, nature, and predictors of groin complications using the Angio-Seal closure device after interventional and diagnostic catheterization were not well defined.
What are the predictors of complications and the learning curve associated with the Angio-Seal closure device following catheterization?
Observational (n=252)
No
What are the predictors of complications and the learning curve associated with the Angio-Seal closure device following catheterization?
The Angio-Seal device can be used with reasonable safety and efficacy after catheterization, with a learning curve observed in the first 50 cases and higher complication risks associated with interventional procedures, postprocedure heparin, and lower BMI.
Answers are grounded in this paper and cite their sources.
May inform single-operator device selection; retrospective data leave generalizability and comparative safety open.
A retrospective study was conducted to determine the frequency and nature of groin complications when the Angio-Seal device was used on 252 occasions by one operator immediately following interventional (66%) and diagnostic (34%) procedures. Sixty-nine percent of the 238 successfully deployed cases received ticlopidine or clopidogrel, 16% received abciximab, and 15% received heparin postprocedure. Complications included vascular surgery for collagen plug perforation into the femoral artery (0.8%), failure to deploy (5.6%), pseudoaneurysm (0.4%), brisk, visible bleeding (9%), persistent ooze (14%), hematoma > 6 cm (0.8%), hematoma </= 6 cm (2.4%), and ecchymosis > 1 cm(2) (10%). Multivariate analysis identified diagnostic cases (6 Fr sheaths) to be associated with a reduced risk of complications [odds ratio (OR) 0.1] while interventional procedures (8 Fr sheaths), postprocedure heparin, and body mass index (BMI) < 28 (OR 10.1, 3.2, and 2.8, respectively) were associated with increased risk. Gender, age, ticlopidine, clopidogrel, and abciximab were not independent predictors of complications. A learning curve for device deployment was observed in the first 50 cases (14% nondeployment vs. 3.5% for the subsequent 202 procedures, P = 0.009) and failure to deploy was independent of sheath size used. Angio-Seal can be used with reasonable safety and efficacy immediately after diagnostic and interventional procedures. Cathet. Cardiovasc. Intervent. 48:162-166, 1999.
No takes yet. Share an insight, caveat, or question.
Warren et al. (1999) conducted an observational in Patients undergoing interventional and diagnostic catheterization (n=252). Angio-Seal closure device was evaluated on Device nondeployment (learning curve: first 50 cases vs subsequent 202 procedures) (p=0.009). A learning curve for Angio-Seal deployment was observed, with a 14% nondeployment rate in the first 50 cases compared to 3.5% in the subsequent 202 procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: